Building on research by a former University of Minnesota professor, Torigen Pharmaceuticals has begun in-veterinary testing of its immunooncology vaccine for companion animals.

Torigen Pharmaceuticals, a US-based veterinary cancer immunotherapy developer based on University of Minnesota research, has closed a $3.1m series A round featuring University of Connecticut-backed UConn Innovation Fund.
UConn Innovation Fund, which also counts state-owned investment firm Connecticut Innovations (CI) and financial services Webster Bank as partners, is a $1.5m vehicle open to participants in the UConn Technology Incubation Program.
CI led the series A round in its own right, with participation from SoGal Ventures, The Fund…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?